New Drug Rules On Licensing, Trials, Surveillance Edge Closer In Singapore
This article was originally published in SRA
Executive Summary
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.
You may also be interested in...
Singapore: Less Than Three Months Left For Companies To Prepare For New Pharma Rules
Singapore's efforts to consolidate and streamline the regulatory control of all health products under a single legislation has resulted in the fine-tuning of certain regulatory provisions that drug companies should be aware of.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.